ST. PAUL, Minn., April 24, 2017 /PRNewswire/
-- EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical
devices using neuroblocking technology to treat obesity, metabolic
diseases and other gastrointestinal disorders, today announced it
has been named a 2017 Bronze Edison Award Winner by the
internationally renowned Edison Awards™ in the Health and Wellness
category for its vBloc® Neurometabolic Therapy for the
treatment of obesity. The Edison Awards, inspired by Thomas Edison's persistence and inventiveness,
recognize innovation, creativity and ingenuity in the global
economy. Award winners were announced April
20, 2017 at the Edison Awards Annual Gala in New York City.
"It's exciting to see companies like EnteroMedics continuing
Thomas Edison's legacy of
challenging conventional thinking," said Frank Bonafilia, Edison Awards' executive
director. "Edison Awards recognizes the game-changing
products and services, and the teams that brought them to
consumers."
Edison Award nominees are judged by more than 3,000 senior
business executives and academics from across the nation whose
votes acknowledge the Finalists' success in meeting the award's
stringent criteria of quality. The Edison Awards is a program
conducted by Edison Universe, a 501(c)(3) charitable organization
dedicated to fostering future innovators. Past winners include
Apple, Fitbit, General Electric, the Mayo Clinic, and
Microsoft.
"We are honored that vBloc Therapy has been recognized by the
Edison Awards for its innovative and cutting-edge approach to
helping people battle obesity," said Dan
Gladney, EnteroMedics President, Chief Executive Officer and
Chairman of the Board. "Having brought to market the first new
medical device approved by the US Food and Drug Administration in
over 10 years for the treatment of obesity, this award continues to
validate the hard work and commitment we have undertaken to ensure
those living with obesity have the best tools possible to help them
achieve their goal of a healthier lifestyle."
vBloc Therapy is approved for use in helping with weight loss in
people aged 18 years and older who are obese, with a BMI of 40 to
45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a
related health condition such as Type 2 diabetes, high blood
pressure, high cholesterol levels or obstructive sleep apnea who
have had a poor response to trying to lose weight under supervision
in the last 5 years.
About the Edison Awards™
Originally established in 1987 by the American Marketing
Association and now a global program conducted by Edison Universe,
the Edison Awards™ have honored some of the world's most innovative
new products, services and business leaders. The Awards are named
after Thomas Alva Edison
(1847-1931), whose extraordinary new product development methods
garnered him 1,093 U.S. patents and made him a household name
around the world. Edison pioneered five industries which
transformed our world, including the incandescent electric light
and the distribution system for electrical power, the phonograph
and recorded sound, the telephone transmitter, the electrical
storage battery, and the motion-picture camera. The Edison Awards
symbolize the persistence and excellence personified by
Thomas Edison, while also
strengthening the human drive for innovation, creativity, and
ingenuity.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases.
vBloc® Neurometabolic Therapy, delivered by a
pacemaker-like device called the vBloc® System, is
designed to intermittently block the vagus nerves using
high-frequency, low-energy, electrical impulses. EnteroMedics'
vBloc® System has received U.S. Food and Drug
Administration approval and CE Mark.
Information about the vBloc® System and
vBloc® Neurometabolic Therapy
You should not have an implanted vBloc® System if you
have cirrhosis of the liver, high blood pressure in the veins of
the liver, enlarged veins in your esophagus or a significant hiatal
hernia of the stomach; if you need magnetic resonance imaging
(MRI); if you have a permanently implanted, electrical medical
device; or if you need a diathermy procedure using heat. The most
common related adverse events that were experienced during clinical
study of the vBloc System included pain, heartburn, nausea,
difficulty swallowing, belching, wound redness or irritation, and
constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please visit www.vbloc.com or
call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about
EnteroMedics Inc. Our actual results could differ materially from
those discussed due to known and unknown risks, uncertainties and
other factors including our limited history of operations; our
losses since inception and for the foreseeable future; our limited
commercial sales experience with our vBloc® System for
the treatment of obesity in the United
States or in any foreign market other than Australia and the European Community; our
ability to maintain compliance with the Nasdaq continued listing
requirements; our ability to commercialize our vBloc®
System; our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption
of our vBloc® System and vBloc®
Neurometabolic Therapy; our ability to obtain third party coding,
coverage or payment levels; ongoing regulatory compliance; our
dependence on third party manufacturers and suppliers; the
successful development of our sales and marketing capabilities; our
ability to raise additional capital when needed; international
commercialization and operation; our ability to attract and retain
management and other personnel and to manage our growth
effectively; potential product liability claims; potential
healthcare fraud and abuse claims; healthcare legislative reform;
and our ability to obtain and maintain intellectual property
protection for our technology and products. These and additional
risks and uncertainties are described more fully in the Company's
filings with the Securities and Exchange Commission, particularly
those factors identified as "risk factors" in the annual report on
Form 10-K filed March 8, 2017. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-vbloc-neurometabolic-therapy-recognized-at-2017-edison-awards-300443752.html
SOURCE EnteroMedics Inc.
